Biobehavioral Implications of Chimeric Antigen Receptor T-cell Therapy: Current State and Future Directions. Transplant Cell Ther 2023 Jan;29(1):19-26
Date
10/09/2022Pubmed ID
36208728DOI
10.1016/j.jtct.2022.09.029Scopus ID
2-s2.0-85143519815 (requires institutional sign-in at Scopus site) 2 CitationsAbstract
Chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable clinical responses in hematologic malignancies. Recent advances in CAR T-cell therapy have expanded its application into other populations including older patients and those with central nervous system and solid tumors. Although its clinical efficacy has been excellent for some malignancies, CAR T-cell therapy is associated with severe and even life-threatening immune-mediated toxicities, including cytokine release syndrome and neurotoxicity. There is a strong body of scientific evidence highlighting the connection between immune activation and neurocognitive and psychological phenomena. To date, there has been limited investigation into this relationship in the context of immunotherapy. In this review, we present a biobehavioral framework to inform current and future cellular therapy research and contribute to improving the multidimensional outcomes of patients receiving CAR T-cell therapy.
Author List
Taylor MR, Steineck A, Lahijani S, Hall AG, Jim HSL, Phelan R, Knight JMAuthors
Jennifer M. Knight MD, MS Associate Professor in the Psychiatry and Behavioral Medicine department at Medical College of WisconsinRachel A. Phelan MD, MPH Associate Professor in the Pediatrics department at Medical College of Wisconsin
Angela S. Steineck MD Assistant Professor in the Pediatrics department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Cell- and Tissue-Based TherapyHumans
Immunotherapy, Adoptive
Neoplasms
Receptors, Antigen, T-Cell
T-Lymphocytes
